A detailed history of Mystic Asset Management, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Mystic Asset Management, Inc. holds 28,240 shares of SUPN stock, worth $1.02 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
28,240
Previous 27,940 1.07%
Holding current value
$1.02 Million
Previous $747,000 17.8%
% of portfolio
0.34%
Previous 0.3%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$25.77 - $35.16 $7,731 - $10,547
300 Added 1.07%
28,240 $880,000
Q2 2024

Aug 08, 2024

SELL
$25.99 - $33.85 $33,787 - $44,005
-1,300 Reduced 4.45%
27,940 $747,000
Q1 2024

May 06, 2024

SELL
$27.11 - $35.17 $2,711 - $3,517
-100 Reduced 0.34%
29,240 $997,000
Q4 2023

Feb 12, 2024

SELL
$22.72 - $29.68 $11,360 - $14,840
-500 Reduced 1.68%
29,340 $849,000
Q3 2023

Nov 13, 2023

BUY
$27.57 - $32.91 $13,785 - $16,455
500 Added 1.7%
29,840 $822,000
Q2 2023

Aug 11, 2023

SELL
$29.91 - $38.73 $41,874 - $54,221
-1,400 Reduced 4.55%
29,340 $881,000
Q4 2022

Feb 03, 2023

SELL
$31.09 - $37.88 $3,109 - $3,788
-100 Reduced 0.32%
30,740 $1.1 Million
Q3 2022

Oct 18, 2022

SELL
$28.79 - $35.41 $50,382 - $61,967
-1,750 Reduced 5.37%
30,840 $1.04 Million
Q2 2022

Aug 12, 2022

SELL
$25.33 - $34.25 $12,665 - $17,125
-500 Reduced 1.51%
32,590 $942,000
Q1 2022

May 11, 2022

BUY
$28.51 - $32.9 $28,510 - $32,900
1,000 Added 3.12%
33,090 $1.07 Million
Q4 2021

Feb 23, 2022

BUY
$26.37 - $34.22 $846,213 - $1.1 Million
32,090 New
32,090 $935,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.94B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Mystic Asset Management, Inc. Portfolio

Follow Mystic Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mystic Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mystic Asset Management, Inc. with notifications on news.